Sapropterin dihydrochloride for the treatment of hyperphenylalaninemias

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 9, 2013, Pages 1207-1218

  Blau, Nenad ^a,b,c  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Inborn errors of metabolism; Phenylalanine; Phenylalanine hydroxylase; Phenylketonuria; Sapropterin; Tetrahydrobiopterin; Tyrosine

Indexed keywords

DIHYDROPTERIDINE REDUCTASE; PHENYLALANINE 4 MONOOXYGENASE; PHENYLALANINE AMMONIA LYASE; SAPROPTERIN; TETRAHYDROBIOPTERIN;

ABDOMINAL PAIN; ARTICLE; COGNITIVE DEFECT; CONFUSION; COUGHING; DIARRHEA; DIET RESTRICTION; DIET THERAPY; DIETARY COMPLIANCE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ENZYME ACTIVITY; EUKARYOTIC CELL; FEVER; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HUMAN; HYPERPHENYLALANINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LOADING TEST; MEDICATION COMPLIANCE; NOSE OBSTRUCTION; NUTRITIONAL REQUIREMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENYLKETONURIA; PROTEIN INTAKE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RHINORRHEA; SORE THROAT; VOMITING;

BIOPTERIN; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; MUTATION; PHENYLALANINE HYDROXYLASE; PHENYLKETONURIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84882382871     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.804064     Document Type: Article

References (74)

1. Werner ER, Blau N, Thony B. Tetrahydrobiopterin: biochemistry and pathophysiology. Biochem J 2011;438:397-414
2. Blau N, Van Spronsen FJ, Levy HL. Phenylketonuria. Lancet 2010;376:1417-27
3. National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16-18, 2000. Pediatrics 2001;108(4):972-82
4. Kure S, Hou DC, Ohura T, et al. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J Pediatr 1999;135:375-8
5. Bernegger C, Blau N. High frequency of tetrahydrobiopterin-responsiveness among hyperphenylalaninemias: A study of 1919 patients observed from 1988 to 2002. Mol Genet Metab 2002;77:304-13
6. Fiege B, Blau N. Assessment of tetrahydrobiopterin (BH4)-responsiveness in phenylketonuria. J Pediatr 2007;150:627-30
7. European Prescribing Information for sapropterin. Available from: http://www.medicines.org.uk/EMC/medicine/21362/SPC/Kuvan+100+mg+soluble+tablets [Last accessed January 2013]
8. US Prescribing Information for sapropterin. Available from: http://www.kuvan.com [Last accessed January 2013]
9. European Medicines Agency. CHMP Assessment Report for Kuvan. Available from: [Accessed January 2013] 2013
10. Levy H, Milanowski A, Chakrapani A, et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomized placebo-controlled study. Lancet 2007;370:504-10
11. Lee P, Treacy EP, Crombez E, et al. Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria. Am J Med Genet A 2008;146A:2851-9
12. Trefz FK, Burton BK, Longo N, et al. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J Pediatr 2009;154:700-7
13. Burton BK, Nowacka M, Hennermann JB, et al. Safety of extended treatment with sapropterin dihydrochloride in patients with phenylketonuria: results of a phase 3b study. Mol Genet Metab 2011;103:315-22
14. Blau N. Sapropterin dihydrochloride for phenylketonuria and tetrahydrobiopterin deficiency. Expert Rev Endocrinol Metab 2010;5:483-94
15. Blau N, Hennermann JB, Langenbeck U, Lichter-Konecki U. Diagnosis, classification and genetics of phenylketonuria and tetrahydrobiopterin (BH4) deficiencies. Mol Genet Metab 2011;104:S2-9
16. Keil S, Anjema K, Van Spronsen F, et al. Long-term follow-up and outcome of phenylketonuria patients on sapropterin: a retrospective study. Pediatrics 2013;Published online 20 May 2013; doi: 10.1542/peds.2012-0001
17. Opladen T, Hoffmann FG, Blau N. An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalaninaemia. J Inerit Metab Dis 2012;35(6):963-73
18. Blau N, Burton KB, Thony B, et al. Phenylketonuria and BH4 deficiencies. UNI-MED Verlag AG; Bremen: 2010
19. Desviat LR, Perez B, Gamez A, et al. Genetic and phenotypic aspects of phenylalanine hydroxylase deficiency in Spain: molecular survey by regions. Eur J Hum Genet 1999;3):386-92
20. National Institutes of Health (NIH) to host a consensus development conference on screening and management for phenylketonuria (PKU). Pediatr Nurs 2000;26(5):539
21. Feillet F, van Spronsen FJ, MacDonald A, et al. Challenges and pitfalls in the management of phenylketonuria. Pediatrics 2010;126:333-41
22. European Society for Phenylketonuria and Allied Disorders. PKU: closing the Gaps in Care. An ESPKU benchmark report on the management of phenylketonuria within EU healthcare economies. Available from: http://www.espku.org/[Last accessed January 2013]
23. van Spronsen FJ, Ahring KK, Gizewska M. PKU-what is daily practice in various centres in Europe? Data from a questionnaire by the scientific advisory committee of the European Society of Phenylketonuria and Allied Disorders. J Inherit Metab Dis 2009;32(1):58-64
24. Blau N, Belanger-Quintana A, Demirkol M, et al. Management of phenylketonuria in Europe: survey results from 19 countries. Mol Genet Metab 2010;99:109-15
25. Ahring K, Belanger-Quintana A, Dokoupil K, et al. Dietary management practices in phenylketonuria across European centres. Clin Nutr 2009;28(3):231-6
26. Belanger-Quintana A, Dokoupil K, Gokmen-Ozel H, et al. Diet in phenylketonuria: a snapshot of special dietary costs and reimbursement systems in 10 international centers. Mol Genet Metab 2011;105:390-4
27. Di Ciommo V, Forcella E, Cotugno G. Living with phenylketonuria from the point of view of children, adolescents, and young adults: a qualitative study. J Dev Behav Pediatr 2012;33(3):229-35
28. Ahring K, Belanger-Quintana A, Dokoupil K, et al. Blood phenylalanine control in phenylketonuria: a survey of 10 European centres. Eur J Clin Nurt 2011;65(2):275-8
29. Walter JH, White FJ, Hall SK, et al. How practical are recommendations for dietary control in phenylketonuria? Lancet 2002;360:55-7
30. Moyle JJ, Fox AM, Arthur M, et al. Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU. Neuropsychol Rev 2007;17(2):91-101
31. Blau N, Erlandsen H. The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Mol Genet Metab 2004;82:101-11
32. Burton BK, Grange DK, Milanowski A, et al. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6Rtetrahydrobiopterin): a phase II, multicentre, open-label, screening study. J Inherit Metab Dis 2007;30:700-7
33. Zurfluh MR, Zschocke J, Lindner M, et al. Molecular genetics of tetrahydrobiopterin responsive phenylalanine hydroxylase deficiency. Hum Mutat 2008;29(1):167-75
34. Heintz C, Cotton RG, Blau N. Tetrahydrobiopterin, its mode of action on phenylalanine hydroxylase and importance of genotypes for pharmacological therapy of phenylketonuria. Hum Mutat 2013;Published online 4 April 2013; doi: 10.1002/humu.22320
35. Blau N. BIOPKU: International database of patients and genotypes causing PKU and tetrahydrobiopterin-responsive HPA/PKU. Available from: http://www.biopku.org/[Last accessed April 2013]
36. Blau N, Belanger-Quintana A, Demirkol M, et al. Optimizing the use of sapropterin (BH4) in the management of phenylketonuria. Mol Genet Metab 2009;96:158-63
37. Utz JR, Lorentz CP, Markowitz D, et al. START, a double blind, placebo-controlled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients. Mol Genet Metab 2012;193-7
38. van Spronsen FJ, de Groot MJ, Hoeksma M, et al. Large neutral amino acids in the treatment of PKU: from theory to practice. J Inherit Metab Dis 2010;33(6):671-6
39. Sarkissian CN, Gamez A, Wang L, et al. Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria. Proc Natl Acad Sci USA 2008;105:20894-9
40. Gamez A, Wang L, Sarkissian CN, et al. Structure-based epitope and PEGylation sites mapping of phenylalanine ammonia-lyase for enzyme substitution treatment of phenylketonuria. Mol Genet Metab 2007;91(4):325-34
41. Biomarin Pharmaceuticals press release. BioMarin Announces Decision to Start Phase 3 Program for PEG-PAL in 2Q. 2013.Available from: http://phx. corporate-ir.net/phoenix.zhtml? c = 106657&p=irolnewsArticle-print&ID= 1738694 [Last accessed January 2013]
42. Ding Z, Harding H, Thony B. State-ofthe-art 2003 on PKU gene therapy. Mol Genet Metab 2003;81:3-8
43. Ding Z, Harding CO, Rebuffat A, et al. Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system. Mol Ther 2008;16(4):673-81
44. Yagi H, Ogura T, Mizukami H, et al. Complete restoration of phenylalanine oxidation in phenylketonuria mouse by a self-complementary adeno-associated virus vector. J Gene Med 2011;13(2):114-22
45. Yagi H, Sanechika S, Ichinose H, et al. Recovery of neurogenic amines in phenylketonuria mice after liver-targeted gene therapy. Neuroreport 2012;23(1):30-4
46. Harding CO. Progress toward cell-directed therapy for phenylketonuria. Clin Genet 2008;74:97-104
47. Thony B, Leimbacher W, Stuhlmann H, et al. Retrovirus-mediated gene transfer of 6-pyruvoyl-tetrahydropterin synthase corrects tetrahydrobiopterin deficiency in fibroblasts from hyperphenylalaninemic patients. Hum Gene Ther 1996;7:1591-7
48. Fernell E, Watanabe Y, Adolfsson I, et al. Possible effect of tetrahydrobiopterin treatment in six children with autism-clinical and positron emission tomography data: a pilot study. Develop Med Child Neurol 1997;39:313-18
49. Frye RE, Delatorre R, Taylor HB, et al. Metabolic effects of sapropterin treatment in autism spectrum disorder: a preliminary study. Translat Psychiatry 2013;3:e237
50. Food and Drug Administration. Medical review (Sapropterin; 6Rtetrahydrobiopterin). Available from: www.fda.gov/cder/foi/nda/2007/ 022181s000-MedR-P1.pdf [Last accessed April 2013]
51. Australian Government Department of Health and Ageing. Australian Public Assessment Report for Sapropterin dihydrochloride. Available from: http://www.tga.gov.au/pdf/auspar/auspar-kuvan. pdf [Last accessed January 2013]
52. Feillet F, Clarke L, Meli C, et al. Pharmacokinetics of Sapropterin in Patients with Phenylketonuria. Clin Pharmacokinet 2008;47(12):817-25
53. Musson DG, Kramer WG, Foehr ED, et al. Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adults. Clin Ther 2010;2):338-46
54. Zurfluh MR, Fiori L, Fiege B, et al. Pharmacokinetics of orally administered tetrahydrobiopterin in patients with phenylalanine hydroxylase deficiency. J Inherit Metab Dis 2006;29(6):725-31
55. Gramer G, Garbade SF, Blau N, Lindner M. Pharmacokinetics of tetrahydrobiopterin following oral loadings with three single dosages in patients with phenylketonuria. J Inherit Metab Dis 2009;32:52-7
56. Blau N. PKU and BH4: advances in phenylketonuria and tetrahydrobiopterin. SPS Verlagsgesellschaft; Heilbronn: 2006
57. Wasserstein M, Burton B, Cederbaum S. Results of a phase II, multicenter, open-label study of sapropterin dihydrochloride in subjects with hyperphenylalaninemia related to primary BH4 deficiency. Presented at: the Annual Meeting of the American Society for Human Genetics (ASHG); 11-15 November 2008; Philadelphia, PA, USA; 2008
58. Burlina A, Trefz FK, Belanger-Quintana A, et al. Second interim analysis of thr Kuvan adult maternal pediatric European registry (KAMPER): patient characteristics. J Inherit Metab Dis 2012;35(Suppl 1):S43
59. Belanger-Quintana A, Burlina A, Alm J, et al. The safety of sapropterin: second interim analysis of thr Kuvan adult maternal pediatric European registry (KAMPER). J Inherit Metab Dis 2012;35(Suppl 1):S43
60. Gokmen Ozel H, Lammardo AM, Motzfeldt K, et al. Use of sapropterin in the management of phenylketonuria: seven case reports. Mol Genet Metab 2013;2):109-11
61. Leuret O, Barth M, Kuster A, et al. Efficacy and safety of BH4 before the age of 4 years in patients with mild phenylketonuria. J Inherit Metab Dis 2012;35:975-81
62. Burton BK, Adams DJ, Grange DK, et al. Tetrahydrobiopterin therapy for phenylketonuria in infants and young children. J Pediatr 2011;158(3):410-15
63. Dhondt JL, Delcroix M, Farriaux JP. Unconjugated pteridines in human milk. Clin Chim Acta 1982;121:33-5
64. Weinmann A, Post M, Pan J, et al. Tetrahydrobiopterin is present in high quantity in human milk and has a vasorelaxing effect on newborn rat mesenteric arteries. Pediatr Res 2010
65. Abadi-Korek I, Shemer J. Risk-sharing scheme in Israel-Kuvan as an allegory. Harefuah 2012;151(6):362-3; 77, 76
66. Burlina A, Blau N. Effect of BH4 supplementation on phenylalanine tolerance. J Inherit Metab Dis 2009;32:40-54
67. Lambruschini N, Perez-Duenas B, Vilaseca MA, et al. Clinical and nutritional evaluation of phenylketonuric patients on tetrahydrobiopterin monotherapy. Mol Genet Metab 2005;86(Suppl 1):54-60
68. Dobrowolski SF, Heintz C, Miller T, et al. Molecular genetics and impact of residual in vitro phenylalanine hydroxylase activity on tetrahydrobiopterin- responsiveness in Turkish PKU population. Mol Genet Metab 2011;10:116-21
69. Hennermann JB, Roloff S, Gebauer C, et al. Long-term treatment with tetrahydrobiopterin in phenylketonuria: treatment strategies and prediction of long-term responders. Mol Genet Metab 2012;3):249-301
70. Djordjevic M, Klaassen K, Sarajlija A, et al. Molecular genetics and genotype-based estimation of BH4-responsiveness in Serbian PKU patients: spotlight on phenotypic implications of p.L48S. JIMD Rep 2013;9:49-58
71. Karacic I, Meili D, Sarnavka V, et al. Genotype-predicted tetrahydrobiopterin (BH4)-responsiveness and molecular genetics in Croatian patients with phenylalanine hydroxylase (PAH) deficiency. Mol Genet Metab 2009;3):165-71
72. Quirk ME, Dobrowolski SF, Nelson BE, et al. Utility of phenylalanine hydroxylase genotype for tetrahydrobiopterin responsiveness classification in patients with phenylketonuria. Mol Genet Metab 2012;1-2):31-6
73. Bueno MA, Gonzalez-Lamuno D, Delgado-Pecellin C, et al. Molecular epidemiology and genotype-phenotype correlation in phenylketonuria patients from South Spain. J Hum Genet 2013;Published online 21 March 2013; doi: 10.1038/jhg.2013.16
74. Couce ML, Boveda MD, Fernandez-Marmiesse A, et al. Molecular epidemiology and BH4-responsiveness in patients with phenylalanine hydroxylase deficiency from Galicia region of Spain. Gene 2013;521:100-4